Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 7/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.39 |
| ▸ | JAK1 | P23458 | 3/20 | 0.39 |
| ▸ | TYK2 | P29597 | 3/20 | 0.39 |
| ▸ | JAK3 | P52333 | 3/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1167231 | 0.90 | JAK2 (0.47) | FPR2HDAC3HDAC8NCOR2KMT2A | |
| SCHEMBL1166384 | 0.90 | KMT2A (0.48) | FPR2HDAC3HDAC8NCOR2KMT2A | |
| SCHEMBL1165816 | 0.88 | FPR2 (0.43) | FPR2HDAC3HDAC8NCOR2KMT2A | |
| SCHEMBL1167363 | 0.87 | HDAC3 (0.43) | FPR2HDAC3HDAC8NCOR2KMT2A | |
| SCHEMBL1167118 | 0.86 | KMT2A (0.44) | FPR2HDAC3HDAC8NCOR2KMT2A | |
| SCHEMBL1165909 | 0.85 | FPR2 (0.42) | FPR2HDAC3HDAC8NCOR2KMT2A | |
| SCHEMBL1167249 | 0.85 | KMT2A (0.39) | HDAC3HDAC8NCOR2KMT2AALDH1A1 | |
| SCHEMBL1167260 | 0.84 | KDM4E (0.41) | HDAC3HDAC8KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL1166361 | 0.82 | KMT2A (0.41) | FPR2HDAC3HDAC8NCOR2KMT2A | |
| SCHEMBL1167240 | 0.82 | MEN1 (0.47) | HDAC3HDAC8NCOR2KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2242743-B1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-08-21 | — | — | EP | claimed |
| US-8288419-B2 | Aminopyrazole derivatives | ACTELION PHARMACEUTICALS, LTD (CH) | 2012-10-16 | — | — | US | claimed |
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION (CH) | 2011-02-10 | — | — | US | claimed |
| EP-2242743-B1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-08-21 | — | — | EP | disclosed |
| US-8288419-B2 | Aminopyrazole derivatives | ACTELION PHARMACEUTICALS, LTD (CH) | 2012-10-16 | — | — | US | disclosed |
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION (CH) | 2011-02-10 | — | — | US | disclosed |
| EP-2242743-A1 | AMINOPYRAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009077954-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | CYP3A43, CYP1A2, CYP3A5 | FPR2 1074/4885HDAC3 1388/4885HDAC8 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.